Our Services
Medical Information
Helpful Resources
Published on: 7/9/2026
Biologics for nasal polyps—including dupilumab, omalizumab, and mepolizumab—typically begin working within 2–8 weeks, reducing nasal congestion and helping restore your sense of smell. Visible polyp shrinkage usually occurs between 8–16 weeks, with maximum benefits reached by 24–52 weeks of consistent treatment.
How quickly biologics work depends on several factors, including disease severity, other treatments you're using, and how closely you follow the prescribed regimen. Talk with your doctor about treatment goals, monitoring, and safety considerations.
Not sure if your symptoms point to nasal polyps or something else? Understanding your symptoms is the first step to getting the right care. Take a free, instant, online symptom check to clarify what may be causing your issues and get personalized guidance on next steps—so you can have a more informed conversation with your doctor and move toward relief faster.
Reviewed for medical accuracy: 07/09/2026
How Fast Do Biologics Shrink Nasal Polyps? Science-Backed Timelines
Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4% of adults worldwide, causing nasal blockage, loss of smell and recurrent infections. When nasal corticosteroids and surgery don't fully control symptoms, biologic therapies can offer targeted relief. But how quickly can you expect to see your polyps shrink?
Below, we break down the science-backed timelines for FDA-approved biologics, what influences response speed and what to discuss with your doctor.
Biologics are lab-made proteins that block specific molecules or pathways in your immune system. In CRSwNP, type 2 inflammation drives polyp growth. The four main biologics approved for nasal polyps each target key mediators:
By interrupting these signals, biologics can reduce inflammation, ease symptoms and shrink polyps.
Clinical trials use endoscopic nasal polyp scores (0–8 total) and patient-reported outcomes to measure improvement. Here's when patients see meaningful changes:
Dupilumab (SINUS-24 and SINUS-52 trials)
Omalizumab (POLYP 1 & 2 trials)
Mepolizumab (SYNAPSE trial)
Reslizumab (small pilot studies)
Most patients notice less congestion and improved breathing well before you see big changes on camera. Your doctor will guide when to repeat endoscopies or scans.
Biologics are generally well tolerated. Common side effects include:
Serious adverse events are rare but can include hypersensitivity. Always report any new or worsening symptoms to your doctor right away.
If you're dealing with persistent nasal polyps, check your symptoms online with Ubie's free AI-powered tool to get personalized insights about your nasal congestion, breathing difficulties, and loss of smell—it takes just 3 minutes and can help you prepare detailed information for your ENT specialist.
While biologics are safe, certain signs warrant prompt attention:
If you experience any of the above, seek emergency care or call your healthcare provider.
Biologics aren't a magic wand, but they can dramatically improve breathing, smell and quality of life over a few months. If you're curious whether you're a candidate, speak to your doctor—and consider trying Ubie's free symptom checker to document your symptoms, track how long you've been experiencing them, and bring organized information that will make your specialist consultation more effective.
(References)
* Bachert C, Han JK, Wagenmann M, Bousquet J, Hellings PW, Hopkins C, Gevaert P, Andia P, Bhatt DL, Fan C, Staudinger H, Gandhi N, Bleier B, Tilles S, Mullol J. Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Type 2 Inflammation (SINUS-24 and SINUS-52): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. *Lancet Respir Med*. 2019 Aug;7(8):720-730. doi: 10.1016/S2213-2600(19)30190-6. PMID: 31201170.
* Gevaert P, Omachi TA, Hopkins C, Smith SG, Bachert C, Canonica GW, Mullol J, Hellings PW, Diamant Z, Zhang Y, Maspero J, Blaisdell BM, Stachler R, Wessell N, Wang Y, Chon Y, Parnes SM. Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps (SYNAPSE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Lancet Respir Med*. 2021 May;9(5):481-492. doi: 10.1016/S2213-2600(20)30501-5. PMID: 33445089.
* Bachert C, Han JK, Desrosiers M, Hellings PW, Mullol J, Schleimer R, Smith SG, Fan C, Staudinger H, Gandhi N, Bleier B, Tilles S, Wagenmann M. Omalizumab for Chronic Rhinosinusitis with Nasal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Allergy Clin Immunol*. 2020 Jan;145(1):354-361.e4. doi: 10.1016/j.jaci.2019.08.026. PMID: 31563721.
* Sisti M, Calamelli E, Pignataro L, Castellani F, Gelardi M. Efficacy of Biologics on Nasal Polyp Score, Sinonasal Outcome Test-22 and Olfaction in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis. *J Clin Med*. 2022 Nov 25;11(23):7008. doi: 10.3390/jcm11237008. PMID: 36498708; PMCID: PMC9738012.
* Poposki K, Karantani I, Vroegop M, Hopkins C, Hellings PW, Gevaert P, Bachert C. Early response to biologics in chronic rhinosinusitis with nasal polyps: a real-world perspective and systematic review. *Rhinology*. 2023 Dec 1;61(6):534-547. doi: 10.4193/Rhin23.155. PMID: 37943033.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.